Rapamycin Combined with α-Cyanoacrylate Contributes to Inhibiting Intimal Hyperplasia in Rat Models
- PMID: 30570064
- PMCID: PMC6317635
- DOI: 10.5935/abc.20180247
Rapamycin Combined with α-Cyanoacrylate Contributes to Inhibiting Intimal Hyperplasia in Rat Models
Abstract
Background: Vein graft restenosis has an adverse impact on bridge vessel circulation and patient prognosis after coronary artery bypass grafting.
Objectives: We used the extravascular supporter α-cyanoacrylate (α-CA), the local application rapamycin/sirolimus (RPM), and a combination of the two (α-CA-RPM) in rat models of autogenous vein graft to stimulate vein graft change. The aim of our study was to observe the effect of α-CA, RPM, and α-CA-RPM on vein hyperplasia.
Methods: Fifty healthy Sprague Dawley (SD) rats were randomized into the following 5 groups: sham, control, α-CA, RPM, and α-CA-RPM. Operating procedure as subsequently described was used to build models of grafted rat jugular vein on carotid artery on one side. The level of endothelin-1 (ET-1) was determined by enzyme-linked immunosorbent assay (ELISA). Grafted veins were observed via naked eye 4 weeks later; fresh veins were observed via microscope and image-processing software in hematoxylin-eosin (HE) staining and immunohistochemistry after having been fixed and stored" (i.e. First they were fixed and stored, and second they were observed); α-Smooth Muscle Actin (αSMA) and von Willebrand factor (vWF) were measured with reverse transcription-polymerase chain reaction (RT-PCR). Comparisons were made with single-factor analysis of variance and Fisher's least significant difference test, with p < 0.05 considered significant.
Results: We found that intimal thickness of the α-CA, RPM, and α-CA-RPM groups was lower than that of the control group (p < 0.01), and the thickness of the α-CA-RPM group was notably lower than that of the α-CA and RPM groups (p < 0.05).
Conclusion: RPM combined with α-CA contributes to inhibiting intimal hyperplasia in rat models and is more effective for vascular patency than individual use of either α-CA or RPM.
Conflict of interest statement
No potential conflict of interest relevant to this article was reported.
Figures




Comment in
-
Synergy of Rapamycin and Cyanoacrylate in Reducing Intimal Hyperplasia.Arq Bras Cardiol. 2019 Jan;112(1):11. doi: 10.5935/abc.20180269. Arq Bras Cardiol. 2019. PMID: 30673011 Free PMC article. No abstract available.
Similar articles
-
Perivenous application of cyanoacrylate tissue sealants reduces intimal and medial thickening of the vein graft and inflammatory responses in a rabbit model of carotid artery bypass grafting.Eur J Cardiothorac Surg. 2016 Feb;49(2):675-81. doi: 10.1093/ejcts/ezv111. Epub 2015 Apr 2. Eur J Cardiothorac Surg. 2016. PMID: 25838460
-
[Local applied slow-releasing rapamycin inhibits neointima hyperplasia in vein graft].Zhonghua Yi Xue Za Zhi. 2006 Jun 27;86(24):1706-9. Zhonghua Yi Xue Za Zhi. 2006. PMID: 16854327 Chinese.
-
Rapamycin-loaded nanoparticles for inhibition of neointimal hyperplasia in experimental vein grafts.Ann Vasc Surg. 2011 May;25(4):538-46. doi: 10.1016/j.avsg.2011.01.003. Ann Vasc Surg. 2011. PMID: 21549923
-
Therapeutics of vein graft intimal hyperplasia: 100 years on.Ann Thorac Surg. 2007 Jul;84(1):317-23. doi: 10.1016/j.athoracsur.2007.02.035. Ann Thorac Surg. 2007. PMID: 17588453 Review.
-
Integrin alpha(v)beta(3) as a target in the prevention of neointimal hyperplasia.J Vasc Surg. 2007 Jun;45 Suppl A(6S):A33-8. doi: 10.1016/j.jvs.2007.02.069. J Vasc Surg. 2007. PMID: 17544022 Free PMC article. Review.
Cited by
-
The effect of lncRNA MIR155HG-modified MSCs and exosome delivery to synergistically attenuate vein graft intimal hyperplasia.Stem Cell Res Ther. 2022 Nov 4;13(1):512. doi: 10.1186/s13287-022-03197-0. Stem Cell Res Ther. 2022. PMID: 36333764 Free PMC article.
-
A novel Nanocellulose-Gelatin-AS-IV external stent resists EndMT by activating autophagy to prevent restenosis of grafts.Bioact Mater. 2022 Oct 25;22:466-481. doi: 10.1016/j.bioactmat.2022.10.013. eCollection 2023 Apr. Bioact Mater. 2022. PMID: 36330163 Free PMC article.
-
Overview of Recent Advances in Experimental Cardiovascular Research.Arq Bras Cardiol. 2020 Oct;115(4):593-594. doi: 10.36660/abc.20200835. Arq Bras Cardiol. 2020. PMID: 33111852 Free PMC article. English, Portuguese. No abstract available.
-
Nano-based perivascular intervention sustains a nine-month long-term suppression of intimal hyperplasia in vein grafts.Bioact Mater. 2024 Oct 13;44:82-96. doi: 10.1016/j.bioactmat.2024.10.005. eCollection 2025 Feb. Bioact Mater. 2024. PMID: 40438256 Free PMC article.
-
Bletilla striata Polysaccharide Prevents Restenosis of Vein Graft Through Inhibiting Cell Proliferation in Rat Model.Cell Transplant. 2020 Jan-Dec;29:963689720969173. doi: 10.1177/0963689720969173. Cell Transplant. 2020. PMID: 33267619 Free PMC article.
References
-
- Blaas I, Heinz K, Wurtinger P, Turkcan A, Tepekoylu C, Grimm M. Vein graft thrombi, a niche for smooth muscle cell colonization - a hypothesis to explain the asymmetry of intimal hyperplasia. J Thromb Haemost. 2016;14(5):1095–1104. - PubMed
-
- Sur S, Sugimoto JT, Agrawal DK. Coronary artery bypass graft: why is the saphenous vein prone to intimal hyperplasia? Can J Physiol Pharmacol. 2014;92(7):531–545. - PubMed
-
- Taggart DP, Ben Gal Y, Lees B, Patel N, Webb C, Rehman SM, et al. A randomized trial of external stenting for saphenous vein grafts in coronary artery bypass grafting. Ann Thorac Surg. 2015;99(6):2039–2045. - PubMed
-
- Parsonnet V, Lari AA, Shah IH. New stent for support of veins in arterial grafts. Arch Surg. 1963 Oct;87:696–702. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous